

FDA-University of Maryland CERSI Public Workshop:
ADEPT 9: Enhancing Diversity in Therapeutics Development for Pediatric Patients
Friday, September 6, 2024 (9:00 AM-5:00 PM)

Welcome & Introduction

- 9:00 AM – 9:05 AM** **Welcome and Overview**
Lily Mulugeta
Associate Director, Division of Pediatrics and Maternal Health (DPMH)
US Food and Drug Administration (FDA)
- 9:05 AM – 9:10 AM** **Introductory Remarks**
Hilary Marston
Chief Medical Officer, US FDA
- 9:10 AM – 9:25 AM** **Opening Presentation**
Mathilda Fienkeng
Director, Office of Medical Policy, US FDA
- 9:25 AM – 9:40 AM** **Keynote Talk**
Michelle and Michael Burgess
International Children's Advisory Network (iCAN) Patient/Parent

Session 1: Current Status of Pediatric Trial Participation and Lessons Learned

- 9:40 AM – 10:00 AM** **FDA Perspective**
Christine Lee
Acting, Associate Commissioner and Director
Office of Minority Health and Health Equity (OMHHE), US FDA
- 10:00 AM – 10:20 AM** **Diversity in Pediatric Research: Academic Perspective**
Sue Rahman
Chief Scientific Officer, Health Data Synthesis Institute
- 10:20 AM – 10:30 AM** **BREAK**
- 10:30 AM – 10:50 AM** **Landscape of Industry Sponsored Pediatric Trials**
Pam Simpkins
Managing Partner, Mezzopointe, LLC
- 10:50 AM – 11:30 AM** **Panel Discussion**
Moderators:
Dionna Green
Director, Office of Pediatric Therapeutics, US FDA
- Lois K Lee*
Senior Associate in Pediatrics, Division of Emergency Medicine

Boston Children's Hospital

Panelists:

Sneha Dave

Executive Director, Generation Patient

Florence Bourgeois

Associate Professor, Pediatrics, Harvard Medical School

Ann McMahon

Regulatory Scientist, Office of Pediatric Therapeutics, US FDA

Pam Simpkins

Managing Partner, Mezzopointe, LLC

Sue Rahman

Chief Scientific Officer, Health Data Synthesis Institute

Christine Lee

Acting, Associate Commissioner and Director, OMMHE, US FDA

11:30 AM – 12:30 PM

LUNCH

Session 2: Inclusion Strategies

12:30 PM – 1:05 PM

Inclusive Trial Designs and Methodological Considerations (Case Examples)

Recruitment and Retention/Decentralized Trials

Rachel Randell

Assistant Professor of Pediatrics

Duke University and Duke Clinical Research Institute (DCRI)

Addressing Diversity in Clinical Trials and Diversity Plans

Ted Love

Chair of Board of Directors, Biotechnology Innovation Organization

Bella Oguno

Vice President, Development Operations, Nuvig Therapeutics

1:05 PM – 1:20 PM

Diversity in Pediatric Type 2 Diabetes Trials

Lauren Wood Heckman

Clinical Reviewer

Division of Diabetes, Lipid Disorders, and Obesity (DLLO), US FDA

1:20 PM – 2:00 PM

Panel Discussion

Moderators:

*Lily Mulugeta
Associate Director, DPMH US FDA*

*Sue Rahman
Chief Scientific Officer, Health Data Synthesis Institute*

Panelists:

*Anvita Ambardekar
High School Student, Pediatric Perspective iCAN*

*Lauren Wood Heickman
Clinical Reviewer, DDLO US FDA*

*Martha Donoghue
Acting Associate Director, Pediatric Oncology, Office of Oncologic Diseases, US FDA*

*LaShell Robinson
Head of Diversity, Equity & Inclusion, Clinical Research Department, Takeda*

*Ki Lee Milligan
Executive Director, Pediatric Center for Excellence, Global Drug Development, Novartis*

*Ted Love (Virtual)
Chair of Board of Directors, Biotechnology Innovation Organization*

*Stephen Balevic (Virtual)
Associate Professor of Medicine and Pediatrics, Duke University and DCRI*

*Rachel Randell
Assistant Professor of Pediatrics, Duke University and DCRI*

*Christina Edwards
Director of Clinical Trials, National Minority Quality Forum*

2:00 PM – 2:15 PM

BREAK

2:15 PM – 3:00 PM

Panel Discussion: Community Engagement and Trust Building

Moderator:

*Carla Epps
Senior Physician, DPMH US FDA*

Panelists:

*Billie Jo Kipp
Clinical Psychologist, Indigenous Innovators Collaborative*

*Nasrin Sari
Patient/Community Representative*

Sneha Dave
Executive Director, Generation Patient

LaToya Williams
Community Clinical Director, Inside Edge Consulting Group

Anvita Ambardekar
High School Student, Pediatric Perspective iCAN

3:00 PM – 3:45 PM

Best Practices That Help Children and Families to Stay in Clinical Trials

Tamora Lewis
Sellers Chair, Pharmacology and Pharmacogenetics
Division Head, Clinical Pharmacology & Toxicology
Staff Neonatologist, The Hospital for SickKids

Puja Umaretiya
Assistant Professor, Division of Pediatric Hematology/Oncology
UT Southwestern, Children's Medical Center

Christina Edwards
Director of Clinical Trials, National Minority Quality Forum

3:45 PM – 4:55 PM

Panel Discussion

Moderators:

Carla Epps
Senior Physician, DPMH US FDA

Billie Jo Kipp
Clinical Psychologist, Indigenous Innovators Collaborative

Panelists:

Lynne Yao
Director, DPMH US FDA

Tamora Lewis
Staff Neonatologist, The Hospital for SickKids

LaToya Williams
Community Clinical Director, Inside Edge Consulting Group

Florence Bourgeois
Associate Professor, Pediatrics, Harvard Medical School

Bella Oguno
Vice President, Development Operations, Nuvig Therapeutics

*Melissa Penn
Director of Patient Engagement R&D, Bayer Pharmaceuticals*

*Michelle/Michael Burgess
iCAN Patient/Family Representative*

*Nasrin Sari
Patient/Community Representative*

*Puja Umaretiya
Assistant Professor, UT Southwestern, Children's Medical Center*

*Christina Edwards
Director of Clinical Trials, National Minority Quality Forum*

4:55 PM – 5:00 PM

Closing Remarks
*Lynne Yao
Director, DPMH US FDA*
